Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Politics, Policy & Law

Congress prevents PRV lapse, postpones reauthorization

Six-year extension of rare pediatric priority review vouchers is likely, Biosecure is a toss-up, other biopharma priorities may have to wait

September 27, 2024 9:14 PM UTC

True to form, America’s lawmakers are procrastinating, putting off decisions about FY25 budgets until well after the Oct. 1 start of the fiscal year and creating suspense over the fate of legislation that would have important public health and economic impacts.

As the 118th Congress winds down, rare pediatric disease priority review vouchers and the Biosecure Act remain in play, while time seems to have run out on efforts to revamp FDA’s regulation of diagnostics and attenuate the Inflation Reduction Act’s disincentives for innovative drug development. Reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) is in a holding pattern but could land before year-end. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article